Europe Biosimilars Market by type (Protein, Insulin, Human Growth Hormones, Granulocyte Colony-stimulating Factor (G-CSF), Interferons, Recombinant Glycosylated Proteins, Erythropoietin, Monoclonal Antibodies, Follitropin, Recombinant Peptides, Glucagon, Calcitonin), by Technology (, Mass Spectroscopy, Chromatography and Others), by Application (Oncology and Blood Diseases, Growth hormone deficiencies and others), by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

Europe Biosimilars Market by type (Protein, Insulin, Human Growth Hormones, Granulocyte Colony-stimulating Factor (G-CSF), Interferons, Recombinant Glycosylated Proteins, Erythropoietin, Monoclonal Antibodies, Follitropin, Recombinant Peptides, Glucagon, Calcitonin), by Technology (, Mass Spectroscopy, Chromatography and Others), by Application (Oncology and Blood Diseases, Growth hormone deficiencies and others), by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

ID: 1144 | Pages: 140 | November 2016 | Region: Europe


The Europe Biosimilars Market was worth $1.77 billion in 2016 and estimated to be growing at a CAGR of 33%, to reach $7.37 billion by 2021. Biosimilars are rapidly growing as one of the most important sectors in the healthcare industry. With increasing healthcare costs, biosimilars are being looked upon as an affordable treatment option. Growing economies are observing comprehensive growth in biosimilars industry from demanding clinical needs of therapeutics. Rise in GDP and healthcare expenditures, and the demand for cost effective therapeutics solution has resulted in the growth of this market.

Biosimilars are made using living cells that treat disease, by recombinant DNA technology and controlled gene expression. Most biosimilars are derived from bacteria, viruses, plants and animals. Biosimilar drugs are used in prevention and cure of various diseases such as rheumatoid arthritis, cancer, chronic kidney failure, oncology, diabetes, heart attacks, autoimmune diseases, growth hormone deficiency, and infectious disease.

Biosimilars offer a cheaper alternative for other biological and synthetic drugs. Across the world, the biosimilars market is driven by aging population and increasing rates of diabetes and chronic disorders. Government support and initiatives play a crucial role. Emerging pharmaceutical markets and lenient government regulations provide some of the major openings this is market. Economic turmoil in Europe is another factor which adds to the demand for biosimilars market. However, high manufacturing cost and complexity, and the availability of low priced generic drugs in the market are some of the major restraints of biosimilars market are facing.

Based on product types, biosimilars are classified into Protein, Insulin, Human Growth Hormones, Granulocyte Colony-stimulating Factor (G-CSF), Interferons, Recombinant Glycosylated Proteins, Erythropoietin, Monoclonal Antibodies, Follitropin, Recombinant Peptides, Glucagon and Calcitonin. Their applications include chronic and autoimmune diseases, blood disorders, oncology disease along with growth hormone deficiency. Furthermore, on the basis of geography, the European Market is analysed under various regions namely, UK, Spain, Italy, Germany and France. Europe dominates the biosimilar market. In the coming years, several new classes of biosimilars are expected to be submitted for approval in Europe. Most existing drugs are expected to lose their EU patents by 2020, including leading treatments for breast cancer, diabetes and rheumatoid arthritis. Overall, the opportunities in biosimilar research are expected to escalate throughout Europe.

Some of the major players in the biosimilars market are Sandoz International GmbH, Wockhardt Ltd, Hospira, Inc., Teva Pharmaceutical Industries Ltd. Dr. Reddy’s Laboratories, Biocon Limited, Mylan, Inc., Zydus Cadila, Celltrion Inc., Roche Diagnostics and Cipla Ltd.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Type                        

                                5.1.1 Protein     

                                5.1.2 Insulin       

                                5.1.3 Human Growth Hormones

                                5.1.4 Granulocyte Colony-stimulating Factor (G-CSF)       

                                5.1.5 Interferons             

                                5.1.6 Recombinant Glycosylated Proteins             

                                5.1.7 Erythropoietin       

                                5.1.8 Monoclonal Antibodies     

                                5.1.9 Follitropin

                                5.1.10 Recombinant Peptides    

                                5.1.11 Glucagon               

                                5.1.12 Calcitonin              

                5.2 By Technology                          

                                5.2.1 Mass Spectroscopy             

                                5.2.2 Chromatography  

                                5.2.3 Monoclonal Antibody Technology

                                5.2.4 Recombinant DNA Technology       

                                5.2.5 Nuclear magnetic resonance (NMR) technology     

                                5.2.6 Electrophoresis     

                                5.2.7 Bioassay   

                5.3 By Application                           

                                5.3.1 Oncology diseases

                                5.3.2 Blood disorders    

                                5.3.3 Growth hormone deficiencies        

                                5.3.4 Chronic and autoimmune diseases

                                5.3.5 Others      

6. Geographical Analysis                                              

                                6.1 Introduction              

                                6.2 U.K

                                6.3 Spain             

                                6.4 Germany     

                                6.5 Italy               

                                6.6 France          

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Sandoz International GmbH                

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Wockhardt                 

                8.3 Hospira                        

                8.4 Teva Pharmaceutical Industries                         

                8.5 Dr. Reddy’s Laboratories                      

                8.6 Biocon                          

                8.7 Mylan                           

                8.8 Zydus Cadila                               

                8.9 Celltrion                       

                8.10 Roche Diagnostics                 

                8.11 Cipla                            

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

                                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Europe Biosimilars Market By Type, From 2016-2021 ( USD Billion )
  2. Europe Protein Market By Region, From 2016-2021 ( USD Billion )
  3. Europe Insulin Market By Region, From 2016-2021 ( USD Billion )
  4. Europe Human Growth Hormones Market By Region, From 2016-2021 ( USD Billion )
  5. Europe Granulocyte Colony-stimulating Factor (G-CSF) Market By Region, From 2016-2021 ( USD Billion )
  6. Europe Interferons Market By Region, From 2016-2021 ( USD Billion )
  7. Europe Recombinant Glycosylated Proteins Market By Region, From 2016-2021 ( USD Billion )
  8. Europe Erythropoietin Market By Region, From 2016-2021 ( USD Billion )
  9. Europe Monoclonal Antibodies Market By Region, From 2016-2021 ( USD Billion )
  10. Europe Follitropin Market By Region, From 2016-2021 ( USD Billion )
  11. Europe Recombinant Peptides Market By Region, From 2016-2021 ( USD Billion )
  12. Europe Glucagon Market By Region, From 2016-2021 ( USD Billion )
  13. Europe Calcitonin Market By Region, From 2016-2021 ( USD Billion )
  14. Europe Biosimilars Market By Technology, From 2016-2021 ( USD Billion )
  15. Europe Mass Spectroscopy Market By Region, From 2016-2021 ( USD Billion )
  16. Europe Chromatography Market By Region, From 2016-2021 ( USD Billion )
  17. Europe Monoclonal Antibody Technology Market By Region, From 2016-2021 ( USD Billion )
  18. Europe Recombinant DNA Technology Market By Region, From 2016-2021 ( USD Billion )
  19. Europe Nuclear magnetic resonance (NMR) technology Market By Region, From 2016-2021 ( USD Billion )
  20. Europe Electrophoresis Market By Region, From 2016-2021 ( USD Billion )
  21. Europe Bioassay Market By Region, From 2016-2021 ( USD Billion )
  22. Europe Biosimilars Market By Application, From 2016-2021 ( USD Billion )
  23. Europe Oncology diseases Market By Region, From 2016-2021 ( USD Billion )
  24. Europe Blood disorders Market By Region, From 2016-2021 ( USD Billion )
  25. Europe Growth hormone deficiencies Market By Region, From 2016-2021 ( USD Billion )
  26. Europe Chronic and autoimmune diseases Market By Region, From 2016-2021 ( USD Billion )
  27. Europe Others Market By Region, From 2016-2021 ( USD Billion )
  28. U.K. Biosimilars Market By Type, From 2016-2021 ( USD Billion )
  29. U.K. Biosimilars Market By Technology, From 2016-2021 ( USD Billion )
  30. U.K. Biosimilars Market By Application, From 2016-2021 ( USD Billion )
  31. Germany Biosimilars Market By Type, From 2016-2021 ( USD Billion )
  32. Germany Biosimilars Market By Technology, From 2016-2021 ( USD Billion )
  33. Germany Biosimilars Market By Application, From 2016-2021 ( USD Billion )
  34. France Biosimilars Market By Type, From 2016-2021 ( USD Billion )
  35. France Biosimilars Market By Technology, From 2016-2021 ( USD Billion )
  36. France Biosimilars Market By Application, From 2016-2021 ( USD Billion )
  37. Italy Biosimilars Market By Type, From 2016-2021 ( USD Billion )
  38. Italy Biosimilars Market By Technology, From 2016-2021 ( USD Billion )
  39. Italy Biosimilars Market By Application, From 2016-2021 ( USD Billion )
  40. Spain Biosimilars Market By Type, From 2016-2021 ( USD Billion )
  41. Spain Biosimilars Market By Technology, From 2016-2021 ( USD Billion )
  42. Spain Biosimilars Market By Application, From 2016-2021 ( USD Billion )
North America High Potency Active Pharmaceutical Ingredients Market By Type (Innovative HPAPI’s And Generic HPAPI’s), By Synthesis (Biotech HPAPI’s And Synthetic HPAPI’s), By Therapeutic Application (Oncolog...
Middle East And Africa High Potency Active Pharmaceutical Ingredients Market By Type (Innovative HPAPI’s And Generic HPAPI’s), By Synthesis (Biotech HPAPI’s And Synthetic HPAPI’s), By Therapeutic Application...
Latin America High Potency Active Pharmaceutical Ingredients Market By Type (Innovative HPAPI’s And Generic HPAPI’s), By Synthesis (Biotech HPAPI’s And Synthetic HPAPI’s), By Therapeutic Application (Oncolog...
Europe High Potency Active Pharmaceutical Ingredients Market By Type (Innovative HPAPI’s And Generic HPAPI’s), By Synthesis (Biotech HPAPI’s And Synthetic HPAPI’s), By Therapeutic Application (Oncology, Glau...
Asia Pacific High Potency Active Pharmaceutical Ingredients Market By Type (Innovative HPAPI’s And Generic HPAPI’s), By Synthesis (Biotech HPAPI’s And Synthetic HPAPI’s), By Therapeutic Application (Oncology...
High Potency Active Pharmaceutical Ingredients Market By Type (Innovative HPAPI’s And Generic HPAPI’s), By Synthesis (Biotech HPAPI’s And Synthetic HPAPI’s), By Therapeutic Application (Oncology, Glaucoma, H...
North America Cannabis Testing Market By Product & Software (Analytical Instruments, Consumables And Software), By Testing Procedures (Terpene Profiling, Potency Testing, Residual Solvent Screening, Pesticide Screen...
Middle East And Africa Cannabis Testing Market By Product & Software (Analytical Instruments, Consumables And Software), By Testing Procedures (Terpene Profiling, Potency Testing, Residual Solvent Screening, Pestici...
Latin America Cannabis Testing Market By Product & Software (Analytical Instruments, Consumables And Software), By Testing Procedures (Terpene Profiling, Potency Testing, Residual Solvent Screening, Pesticide Screen...
Europe Cannabis Testing Market By Product & Software (Analytical Instruments, Consumables And Software), By Testing Procedures (Terpene Profiling, Potency Testing, Residual Solvent Screening, Pesticide Screening, Ge...
Asia Pacific Cannabis Testing Market By Product & Software (Analytical Instruments, Consumables And Software), By Testing Procedures (Terpene Profiling, Potency Testing, Residual Solvent Screening, Pesticide Screeni...
Global Cannabis Testing Market By Product & Software (Analytical Instruments, Consumables And Software), By Testing Procedures (Terpene Profiling, Potency Testing, Residual Solvent Screening, Pesticide Screening, Ge...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
502, Kakatiya's Empire,
Jubilee Gardens, Hyderabad,
Telangana, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2017 Market Data Forecast
All Rights Reserved.